Multiple roles of macrophage migration inhibitory factor in pulmonary hypertension

Pulmonary hypertension (PH) is a life-threatening condition arising from the loss and obstructive remodeling of the pulmonary arteries, leading to the sustained elevation of pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) and subsequently right ventricular (RV) failure and...

Full description

Saved in:
Bibliographic Details
Published in:American journal of physiology. Lung cellular and molecular physiology 2020-01, Vol.318 (1), p.L1-L9
Main Authors: Jalce, Gael, Guignabert, Christophe
Format: Article
Language:English
Subjects:
Animals
Arteries
Biomarkers
Blood pressure
Cardiology and cardiovascular system
Cellular Biology
Drug development
Heart
Human health and pathology
Humans
Hypertension
Hypertension, Pulmonary - metabolism
Hypertension, Pulmonary - physiopathology
Inflammation
Leukocyte migration
Life Sciences
Lung diseases
Macrophage migration inhibitory factor
Macrophage Migration-Inhibitory Factors - metabolism
Macrophages - metabolism
Macrophages - physiology
Migration inhibitory factor
Obstructive lung disease
Pulmonary arteries
Pulmonary artery
Pulmonary Artery - metabolism
Pulmonary Artery - physiopathology
Pulmonary hypertension
Pulmonology and respiratory tract
Target recognition
Therapeutic applications
Thromboembolism
Vascular Remodeling
Vascular Resistance - physiology
Ventricle
Ventricular Dysfunction, Right - metabolism
Ventricular Dysfunction, Right - physiopathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pulmonary hypertension (PH) is a life-threatening condition arising from the loss and obstructive remodeling of the pulmonary arteries, leading to the sustained elevation of pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) and subsequently right ventricular (RV) failure and death. PH encompasses a group of multifactorial diseases, such as pulmonary arterial hypertension (PAH) and chronic thromboembolic PH, for which there is no treatment that can stop or reverse the progression of remodeling of the pulmonary vasculature. The identification of new molecular targets for the development of more effective drugs is thus urgently needed. In this context, macrophage migration inhibitory factor (MIF), a pleiotropic upstream proinflammatory mediator, is emerging as a promising molecular target, as it contributes to perivascular inflammation and pulmonary arterial remodeling, two key hallmarks of PAH that are not specifically targeted by currently approved therapies. The objective of this review is to summarize the scientific evidence on the pathogenic roles of MIF and its potential as a biomarker and therapeutic target in PH/PAH.
ISSN:1040-0605
1522-1504
DOI:10.1152/ajplung.00234.2019